OBJECTIVES The main objective of this study was to estimate the health‑economic impact of sensor augmented pump (SAP) compared to pump therapy alone (CSII) in uncontrolled type 1 diabetes (T1DM) in France. METHODS The Core Diabetes Model was used to project the incidence of diabetes‑related complications over a lifetime horizon, based on a recently performed meta‑analysis comparing SAP versus CSII. The meta‑analysis showed that for the analysed cohort of T1DM using exclusively Medtronic devices with average baseline HbA1c of 9%, 70% use of SAP led to a reduction of ‑0.88% versus ‑0.47% HbA1c, for SAP and CSII respectively. The mean baseline age of the simulated cohort was, according to a French typical TD1M population, 36 years, with a mean duration of diabetes of 17 years. The quality of life was adjusted for a reduced fear of hypoglycaemic event in the SAP arm. Sensitivity analyses were carried out on several key parameters. RESULTS The incremental cost‑effectiveness ratio (ICER) was 27,796 € per Quality Adjusted Life Year gained (QALY). The improvement in discounted QALY was 1.27 years in favour of SAP. Undiscounted life expectancy was increased by 1 year for SAP versus CSII. Additional SAP related costs were partially offset by the savings due to the reduction in diabetes related complications and the lower frequency of SMBG tests. Remaining extra annual costs for SAP were 1,258 € per patient. When indirect costs were considered, the ICER was reduced to 23,300 € per QALY. CONCLUSIONS Using a well‑accepted simulation model in an uncontrolled T1DM, projection of the improvement in HbA1c of SAP versus CSII translated into cost‑effective ratio, generally considered as very good value for money in France. Extensive sensitivity analysis on key drivers confirmed the robustness of results under a wide range of assumptions.